U.S. Markets closed

Biomerica, Inc. (BMRA)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
2.64-0.06 (-2.05%)
At close: 4:00PM EDT
People also watch
Interactive chart
Previous Close2.70
Bid0.01 x 100
Ask4.00 x 100
Day's Range2.64 - 2.66
52 Week Range1.41 - 3.38
Avg. Volume15,476
Market Cap22.33M
PE Ratio (TTM)-11.95
Earnings DateN/A
Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • Zacks Small Cap Researchlast month

    BMRA: Base Business Bouncing Back With Three Quarters of Sequential Growth

    Revenue from Asia was $448k, up 22% from $367k in Q3 2016 (i.e. Europe has not been nearly as positive which saw sales fall 20% in fiscal 2016 and shed another 7% through the first half of fiscal 2017.  But while one quarter does not make a trend, the most recent period bucked the prior 18-months of disappointing sales.  Q3 ’17 European revenue of $654k was 20% better than the prior year number, up 41% from Q2 and the highest since Q4 2015.  While Biomerica has never provided much in the way of detailed trends effecting revenue, they do note in the Q3 10-Q that an increase in sales of clinical laboratory products benefitted both their Asian and European segments.  As we noted in previous updates, we viewed recent signs of European revenue stabilizing around ~$500k/quarter as encouraging relative to the potential for this territory to return to positive growth in the coming (i.e.

  • Capital Cubelast month

    Biomerica, Inc. :BMRA-US: Earnings Analysis: Q3, 2017 By the Numbers : April 18, 2017

    Categories: Yahoo FinanceGet free summary analysis Biomerica, Inc. reports financial results for the quarter ended February 28, 2017. Highlights Summary numbers: Revenues of USD 1.50 million, Net Earnings of USD -0.30 million. Gross margins widened from 25.30% to 29.96% compared to the same period last year, operating (EBITDA) margins now -17.68% from -15.49%. Change in operating cash ... Read more (Read more...)

  • Zacks Small Cap Research4 months ago

    BMRA: Analysis of IBS Drugs Indicates Unmet Need for Alternative Therapies

    Biomerica (BMRA) reported financial results for their fiscal second quarter ending November 30.  Revenue, for the second straight quarter, surprised on the upside by about 12% relative to our estimate with the majority of the beat in both periods related to stronger than anticipated sales in Asia.  Similarly, it wasn’t just revenue that impressed, gross margin also came in much wider than we modeled – again for the second straight quarter. Q2 revenue of $1.4M was up 23% yoy, up 2% sequentially and about 12% better than our $1.3M estimate.  It was also the highest since fiscal Q4 2015 (May 2015).  While revenue in both Europe and the U.S., which account for approximately 35% and 15% of total revenue, respectively, saw revenue decline on both a yoy and sequential basis, this was more than offset by relatively very strong sales in Asia, which accounts for ~45% of total revenue.